M.H.SA. / ForSight Labs / Upjohn Company / Allergan Inc. / AMD / Neurotech Pharmaceuticals Inc. / /
Country
Mexico / Japan / /
Currency
USD / /
Event
FDA Phase / Company Expansion / Employment Change / /
Facility
Temple University / National Eye Institute / University of Southern Alabama College / University of Juarez / University of Illinois / Doheny Eye Institute / Columbia University / Duke University / University of Southern California / Wilmer Eye Institute / University of South Alabama Medical Center / University of Michigan / Henry Ford Hospital / University of California at Irvine / University of California / Wilmer Ophthalmological Institute / /
IndustryTerm
therapies for chronic retinal disease / biotechnology / treatment of retinal disease / therapeutics for the treatment of chronic retinal diseases / transformational technology / unit dose products / pharmaceutical products / therapies for retinal disease / /
Wilmer Eye Institute / National Eye Institute / Columbia University / University of California / Southern Alabama College of Medicine / Health Services Administration / South Alabama Medical Center / University of Juarez / Duke University / Temple University / University of Illinois / School of Engineering and Applied Sciences / Board of Directors and Management Team / Duke University Eye Center / Glaucoma Research Foundation / Johns Hopkins University School of Medicine / University of Southern California / Henry Ford Hospital / Wilmer Ophthalmological Institute / FDA / Doheny Eye Institute / University of California / Los Angeles / University of South Alabama / European Union / University of California / San Francisco / the University of Michigan / Wilmer Eye Institute at Johns Hopkins University School of Medicine / /
Person
Eugene de Juan / Rhett Schiffman / Jim Mazzo / Ted Danse / Lester Kaplan / /
Position
advisor / Chairman Board of Directors Executive / retinal surgeon / inventor and entrepreneur / Vice President and Therapeutic Area Head / Vice-Chairman / retinal surgeon / professor of ophthalmology / Chief Medical Officer / CEO / leader / Vice President of Global Drug / Vice President of Global Drug Development and Therapeutic Area Head / President and CEO / Executive Vice President and President / Research & Development / and a board member / board member / /
FOR IMMEDIATE RELEASE Neurotech Pharmaceuticals Adds Ophthalmic Leaders to Advance Groundbreaking Sight-Saving Therapies -- Strengthens Board of Directors and Management Team -Cumberland, RI. – September 19, 2013 – N